Aphton Corp.
8 Penn Center
1628 JFK Boulevard Suite 2300
Philadelphia,
PA 19103
United States - Map
Phone: 215-218-4340
Fax: 215-218-4357
Web Site: http://www.aphton.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 66 |
|
| Aphton Corporation, a clinical stage biopharmaceutical company, engages in the research and development of cancer immunotherapies. It offers products based on its proprietary active immunization, as well as monoclonal antibody technologies. The companys products include IGN101, a Phase II/III randomized double-blind clinical trial in non small cell lung cancer patients, is a cancer vaccine designed to induce an immune response against epithelial cell adhesion molecule positive tumor cells; IGN311, which completed an open-label dose escalating Phase I trial, is a monoclonal antibody targeting Lewis Y-positive cancer cells; and Insegia, which is under various clinical trials for gastrointestinal cancers and non cancer diseases, is designed to target and inhibit the activity of the gastrin hormone. Its preclinical research and development programs focus on a second generation of gastrin immunotherapeutics, including monoclonal antibodies directed against the same gastrin species. Aphton has strategic alliances with BioWa, Inc.; Celltrion, Inc.; Daiichi Pure Chemicals Co.; and Xoma (US) LLC. The company was founded in 1981 and is headquartered in Philadelphia, Pennsylvania. On May 23, 2006, Aphton Corp filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 29, 2007. |
|
| Key Statistics |
| |
No officers available for APHTQ.PK |
0.20% Nasdaq 
0.00 (4.76%) 
Profile
